Clinical Study of Balofloxacin on Infectious Enteritis and Assessment of the Fecal Drug Concentration and Intestinal Microbial Flora in Patients with Infectious Enteritis
-
- OBANA Mitsuo
- Department of Internal Medicine, Kawasaki Municipal Hospital
-
- IRIMAJIRI Shoichiro
- Department of Infectious Diseases, Sapporo City General Hospital
-
- TOMIZAWA Isao
- Department of Infectious Diseases, Sapporo City General Hospital
-
- TAKIZAWA Yoshihiko
- Department of Infectious Diseases, Sapporo City General Hospital
-
- SAKAMOTO Yumiko
- Department of Infectious Diseases, Sapporo City General Hospital
-
- NITTA Yoshiro
- Department of Infectious Diseases, Tokyo Metropolitan Toshima General Hospital
-
- TSUNODA Takafumi
- Department of Infectious Diseases, Tokyo Metropolitan Toshima General Hospital
-
- FUKUDA Hiroyuki
- Department of Infectious Diseases, Tokyo Metropolitan Toshima General Hospital
-
- YAMAGUCHI Tsuyoshi
- Department of Infectious Diseases, Tokyo Metropolitan Komagome General Hospital
-
- MASUDA Gohta
- Department of Infectious Diseases, Tokyo Metropolitan Komagome General Hospital
-
- NEGISHI Masayoshi
- Department of Infectious Diseases, Tokyo Metropolitan Komagome General Hospital
-
- AJISAWA Atsushi
- Department of Infectious Diseases, Tokyo Metropolitan Komagome General Hospital
-
- MURATA Misako
- Department of Infectious Diseaes, Tokyo Metropolitan Bokutoh General Hospital
-
- OHNISHI Kenji
- Department of Infectious Diseaes, Tokyo Metropolitan Bokutoh General Hospital
-
- SAGARA Hiroko
- Department of Infectious Diseaes, Tokyo Metropolitan Bokutoh General Hospital
-
- SAJIMA Yoshikiyo
- Department of Infectious Diseaes, Tokyo Metropolitan Bokutoh General Hospital
-
- MATSUMOTO Fumio
- Department of Infectious Diseases, Department of Gastroenterology Department of Internal Medicine, Kanagawa Prefectural Midwives and Nurses Training School Hospital
-
- IMAI Takero
- Department of Infectious Diseases, Department of Gastroenterology Department of Internal Medicine, Kanagawa Prefectural Midwives and Nurses Training School Hospital
-
- SAKURAI Iwao
- Department of Infectious Diseases, Department of Gastroenterology Department of Internal Medicine, Kanagawa Prefectural Midwives and Nurses Training School Hospital
-
- TAKAHASHI Takayuki
- Department of Infectious Diseases, Department of Gastroenterology Department of Internal Medicine, Kanagawa Prefectural Midwives and Nurses Training School Hospital
-
- KATO Koji
- Department of Communicable Diseases, Department of Gastroerology, Nagoya City Higashi General Hospital
-
- MORI Masamiki
- Department of Communicable Diseases, Department of Gastroerology, Nagoya City Higashi General Hospital
-
- HOSODA Shiro
- Second Department of Internal Medicine, Shiga University of Medical Science
-
- BAMBA Tadao
- Second Department of Internal Medicine, Shiga University of Medical Science
-
- SASAKI Masaya
- Second Department of Internal Medicine, Shiga University of Medical Science
-
- TATEWAKI Kenichi
- Second Department of Internal Medicine, Shiga University of Medical Science
-
- FUSE Kenji
- Second Department of Internal Medicine, Shiga University of Medical Science
-
- SAKUMOTO Hiroshi
- Second Department of Internal Medicine, Shiga University of Medical Science
-
- IWASAKI Yoshiaki
- Second Department of Internal Medicine, Shiga University of Medical Science
-
- OHKUBO Hideo
- Department of Communicable Diseases, Kyoto City Hospital
-
- KIM Yong-ki
- Department of Communicable Diseases, Kyoto City Hospital
-
- AKAO Mitsuru
- Department of Internal Medicine, Infectious Diseases Center, Osaka Municipal Momoyama Hospital
-
- SAKAUE Yoshihiro
- Department of Internal Medicine, Infectious Diseases Center, Osaka Municipal Momoyama Hospital
-
- TOJO Kaneko
- Department of Internal Medicine, Infectious Diseases Center, Osaka Municipal Momoyama Hospital
-
- AMATSU Junko
- Department of Internal Medicine, Infectious Diseases Center, Osaka Municipal Momoyama Hospital
-
- YOSHIDA Hideki
- Department of Internal Medicine, Infectious Diseases Center, Osaka Municipal Momoyama Hospital
-
- YOSHIKAWA Kunio
- Second Department of Internal Medicine, Shiga University of Medical Science
-
- AISAKA Tadakazu
- Department of Internal Medicine, Hiroshima City Funairi Hospital
-
- MIKAMI Motoko
- Department of Internal Medicine, Hiroshima City Funairi Hospital
-
- KURIMURA Osamu
- Second Department of Internal Medicine, Kure National Hospital
-
- KAGAWA Kazunori
- Second Department of Internal Medicine, Kure National Hospital
-
- MATSUBARA Yoshio
- Department of Internal Medicine, Kiyose Jogu Hospital
-
- IMAGAWA Yatsuka
- Department of Environmental Microbiology, College of Environmental Health Azabu University
-
- FUKUYAMA Masafumi
- Department of Environmental Microbiology, College of Environmental Health Azabu University
-
- SAITO Makoto
- Foundation Association of Tokyo City Preventive Medicine
Bibliographic Information
- Other Title
-
- 感染性腸炎に対するBalo floxacinの臨床的研究および感染性腸炎患者における糞便中薬剤濃度と腸内細菌叢の検討
- カンセンセイ チョウ エン ニ タイスル Balofloxacin ノ リンシ
Search this article
Abstract
The efficacy, safety and usefulness of balofloxacin (BLFX) for patients with acute infectious enteritis and the carriers mainly shigellosis, were investigated. The drug was administered at a daily dose of 200 mg twice a day for 3 days to patients with cholera, 7 days to patients with Salmonella enteritis and 5 days to patients with other conditions of infectious enteritis including shigellosis;<BR>1. The efficacy was analyzed in 89 of the 135 patients who received the administration (43 patients with shigellosis, 14 with Salmonella enteritis, 8 with enteropathogenic/enterotoxigenic Escherichia coli enteritis, 3 with cholera, 7 with enteritis with other pathogenic bacteria, 6 with polymicrobial infectious enteritis and 8 with acute enteritis that was pathogen-negative).<BR>2. In patients bearing symptoms and who thus could be analyzed for drug efficacy, the drug was markedly effective or effective 50/52 (96.2%).<BR>3. Bacteriologically, the drug was effective for Shigella spp. in 41 (100%) of 41, Salmonella spp. in 12 (85.7%) of 14, and enteropathogenic/enterotoxigenic Escherichia coli in 8 of 8 cases.<BR>4. Adverse effects were seen in 5/133 patients (3.8%) receiving the drug, including two cases of skin eruption, one of numbness of the hands, one of oral aphtha, and one of nausea. In patients for whom laboratory findings were available, 20/115 (17.4%) showed abnormalities, mainly elevations of GOT and/or GPT, but these were slight.<BR>5. In terms of subjective reports of usefulness, 51/82 (62.2%) were markedly satisfied, and 73/82 (89.0%) were either satisfied or markedly satisfied.<BR>6. The influence of administration of BLFX on fecal concentration and intestinal microbial flora was investigated in 2 patients with acute infectious enteritis. Results approximately equivalent to such flora levels in healthy subjects were obtained.<BR>These results suggest that BLFX is highly useful for infectious enteritis such as that caused by shigellosis.
Journal
-
- Kansenshogaku Zasshi
-
Kansenshogaku Zasshi 69 (9), 991-1006, 1995
The Japanese Association for Infectious Diseases
- Tweet
Details
-
- CRID
- 1390282680022330752
-
- NII Article ID
- 130004330416
- 10008727145
- 10008727147
-
- NII Book ID
- AN00047715
-
- ISSN
- 1884569X
- 03875911
-
- NDL BIB ID
- 3644783
-
- PubMed
- 7594801
-
- Data Source
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
-
- Abstract License Flag
- Disallowed